{"url_path":"/sec/kapa/8-k/2026-07-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ** **Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-033289-index.html","accession_number":"0001493152-26-033289","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-033289-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":153,"has_tables":true,"body_markdown":"**Item 8.01.** **Other Events.**\n\n \n\nOn\nJuly 15, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release reporting interim safety data from the Company’s\nongoing Phase 1 clinical trial evaluating ENV-105 (Carotuximab), in combination with osimertinib, in patients with advanced EGFR-mutated\nnon-small cell lung cancer. A copy of the press release is furnished herewith as Exhibit 99.1.\n\n \n\nThe\ninformation in this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed\n“filed” for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),\nor otherwise subject to the liabilities of such Section. The information in this Current Report on Form 8-K shall not be deemed to be\nincorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly\nset forth by specific reference in such filing."}